MyomoMYO
MYO
About: Myomo Inc is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device. The company provides the devices to patients and bills their insurance companies directly, sometimes utilizing the clinical services of orthotics and prosthetics providers for which a fee is paid. The company sells the product to orthotics and prosthetics providers around the world and the Veterans Health Administration (VA).
Employees: 185
0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
725% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 4
439% more call options, than puts
Call options by funds: $399K | Put options by funds: $74K
139% more capital invested
Capital invested by funds: $39.4M [Q3] → $94.1M (+$54.7M) [Q4]
71% more funds holding
Funds holding: 41 [Q3] → 70 (+29) [Q4]
50% more funds holding in top 10
Funds holding in top 10: 2 [Q3] → 3 (+1) [Q4]
25% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 12
11.41% more ownership
Funds ownership: 32.54% [Q3] → 43.95% (+11.41%) [Q4]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$9.50
96%
upside
Avg. target
$10.50
117%
upside
High target
$11
127%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
Ascendiant Capital Edward Woo 42% 1-year accuracy 34 / 81 met price target | 127%upside $11 | Buy Maintained | 17 Mar 2025 |
HC Wainwright & Co. Sean Lee 57% 1-year accuracy 17 / 30 met price target | 96%upside $9.50 | Buy Maintained | 12 Mar 2025 |
Craig-Hallum Craig Knickerbocker 0% 1-year accuracy 0 / 3 met price target | 127%upside $11 | Buy Maintained | 11 Mar 2025 |
Financial journalist opinion
Neutral
Business Wire
2 weeks ago
Myomo Announces Upcoming Changes to its Board of Directors
BURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that directors Amy Knapp and Yitzchak Jacobovitz have informed the board they will not stand for re-election as Class II directors. Ms. Knapp has been a director since July 2016 and Mr. Jacobovitz has served on Myomo's board since January 2.
Neutral
Business Wire
3 weeks ago
Myomo to Present at the 24th Annual Needham Virtual Healthcare Conference
BURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that Paul Gudonis, president and chief executive officer and David Henry, chief financial officer, will present at the 24th Annual Needham Virtual Healthcare Conference, being held from April 7th to April 10th, and will be holding one-on-on.
Negative
Zacks Investment Research
1 month ago
Myomo, Inc. (MYO) Reports Q4 Loss, Tops Revenue Estimates
Myomo, Inc. (MYO) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to loss of $0.07 per share a year ago.
Neutral
Seeking Alpha
1 month ago
Myomo, Inc. (MYO) Q4 2024 Earnings Call Transcript
Myomo, Inc. (NYSE:MYO ) Q4 2024 Earnings Conference Call March 10, 2025 4:30 PM ET Company Participants Tirth Patel - Alliance Advisors, Investor Relations Paul Gudonis - Chief Executive Officer Dave Henry - Chief Financial Officer Conference Call Participants Chase Knickerbocker - Craig-Hallum Scott Henry - AGP Anthony Vendetti - Maxim Group Sean Lee - H.C. Wainwright Edward Woo - Ascendiant Capital Operator Good afternoon, and welcome to the Myomo Fourth Quarter 2024 Earnings Conference Call.
Neutral
Business Wire
1 month ago
Myomo's Fourth Quarter Financial Results Feature Record Revenue of $12.1 Million
BURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today reported financial results for the three months and year ended December 31, 2024. Financial and operating highlights for the fourth quarter of 2024 include the following (all comparisons are with the fourth quarter of 2023 unless otherwise indicated).
Neutral
Business Wire
1 month ago
Myomo to Report Fourth Quarter 2024 Financial Results on March 10
BURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the fourth quarter and year ended December 31, 2024 on March 10, 2025. The Company will host a conference call the same day at 4:30 p.m. ET with prepared remarks by Paul R. Gudonis, chairman and chi.
Positive
MarketBeat
2 months ago
3 Underrated Robotics Stocks Poised for Major Growth
The days of robots being primarily limited to manufacturing applications are long gone—the industry is expanding rapidly and becoming integrated into many different sectors thanks to rapid developments in AI and automation. Analysts expect this to lead to major growth for the industry in the years to come, with an anticipated CAGR of more than 15% in the coming seven years to reach a size of nearly $170 billion globally by 2032.
Positive
MarketBeat
4 months ago
Top 3 Cutting-Edge Micro-Caps Set for 2025 Growth
As 2025 approaches, several promising micro-cap stocks are gaining attention for their potential to disrupt key industries. These companies, though small in market size, are making significant strides with innovative technologies and strategic advancements.
Neutral
Business Wire
4 months ago
Myomo, Inc. Prices $15.0 Million Public Offering of Common Stock
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, today announced that it has priced an underwritten public offering of 3,000,000 shares of its common stock at a public offering price of $5.00 per share. Myomo expects the gross proceeds from this offering to be approximately $15.0 million, before deducting the underwriting discount.
Neutral
Business Wire
4 months ago
Myomo, Inc. Announces Proposed Public Offering of Common Stock
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. In connection with the offering, Myomo also expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares of common stock offered in t.
Charts implemented using Lightweight Charts™